Label Changes for:

Noxafil (posaconazole) Oral Suspension

June 2012

Changes have been made to the CONTRAINDICATIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2010 and June 2012

 

June 2012

 

CONTRAINDICATIONS

HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4
  • Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis.
 
Hide
(web2)